Morphic Holding Inc (MORF) USD0.0001
Morphic Holding, Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing a pipeline of oral small molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Company is advancing its pipeline, including its lead product candidate, MORF-057, an Alpha 4 and Beta 7-specific integrin inhibitor affecting inflammation, for the treatment of inflammatory bowel disease (IBD). It has also developed oral αvb6-specific integrin inhibitors including MORF-720 and MORF-627, for the treatment of fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The Company is using its MInT Platform to advance a pipeline of preclinical programs across a variety of therapeutic areas.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.